DS
PRDS

David Shaw’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

David Shaw’s Portfolio PRDS Stock Details PRDS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-57,072
Closed -$175K – 5673
2022
Q2 		$175K Buy
57,072
+29,799
+109% +$182K ﹤0.01% 4593
2022
Q1 		$197K Sell
27,273
-10,766
-28% -$106K ﹤0.01% 4875
2021
Q4 		$623K Sell
38,039
-9,161
-19% -$107K ﹤0.01% 4277
2021
Q3 		$470K Hold
47,200
– – ﹤0.01% 4122
2021
Q2 		$472K Buy
+47,200
New +$474K ﹤0.01% 4065

Other funds holding PRDS

FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VS
VK Services Menlo Park, California $1.01M AUM 157.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
FCOMV
Foresite Capital Opportunity Management V Larkspur, California $33.3M AUM 47.04% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return

David Shaw's PRDS Position: Q3 2022 in Review

David Shaw sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2022, closing a stake of 57,072 shares — an estimated $175K sold.

David Shaw first reported a position in PRDS in Q2 2021 and held it in 5 quarters. The position peaked at $623K in Q4 2021. 68 funds tracked by Wall St. Rank hold PRDS as of Q3 2022.

  • David Shaw reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • David Shaw sold 57,072 Pardes Biosciences, Inc. Common Stock shares in Q3 2022, an estimated $175K.
  • David Shaw first reported a position in Pardes Biosciences, Inc. Common Stock in Q2 2021 and held it in 5 quarters.
  • David Shaw's Pardes Biosciences, Inc. Common Stock position peaked at $623K in Q4 2021.
  • 68 funds tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.